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"When the heart is diseased, its work is imperfectly performed:  
the vessels proceeding from the heart become inactive, so that you cannot feel them … if the heart 
trembles, has little power and sinks, the disease is advanced and death is near." 




1. Introduction    
Ventricular tachycardia (VT) and ventricular fibrillation (VF) are not uncommon in patients 
with end-stage heart failure. With the shortage of donor cardiac allografts, most potential 
heart transplant recipients are now being bridged with continuous-flow left ventricular 
assist devices (LVADs).  In addition, with the recent FDA approval of the HeartMate® II 
LVAD (Thoratec Corp., Pleasanton, CA) as a destination therapy (DT) device, the potential 
pool of patients that may benefit from this therapy has expanded almost exponentially. 
While ventricular arrhythmias are common in patients with all types of cardiomyopathy 
and heart failure, the effect of LVAD therapy on the incidence of new, or the persistence of 
old ventricular arrhythmias is unknown.  Recent evidence has suggested a possible increase 
in the rates of VT/VF in patients undergoing LVAD therapy with continuous flow devices 
as opposed to older pulsatile devices (Ziv et al, 2005);(Andersen et al., 2009).  The potential 
utility of ventricular ablative procedures at the time of continuous flow LVAD placement is 
unclear.  We have implanted 51 continuous flow LVADs over the past 21 months.  Because 
the incidence of clinically significant post-operative VT/VF was initially higher than what 
he had experienced with earlier generation pulsatile LVADs, we have recently become 
aggressive at treating VT/VF at the time of LVAD placement.  Any patient with a history of 
previous VT/VF has substrate localization performed via electrophysiologic (EP) mapping 
or systematic EKG analysis prior to LVAD placement.  Intraoperatively, the endocardium is 
ablated through the LVAD ventriculotomy with cryoablation in addition to epicardial 
ablation also carried out with cryoablation. Since implementing this algorithm, the incidence 
of clinically significant post-operative VT/VF requiring additional catheter ablation has 
fallen to zero. We recommend aggressive localization and subsequent intra-operative 
ablation for all patients with a history of significant or worsening VT/VF prior to 
continuous flow LVAD placement to decrease the need for post-operative medical or 
catheter-based anti-arrhythmic therapy and to improve outcomes. 
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2.1 Heart failure 
Cardiovascular disease remains the leading cause of death in the United States and other 
industrialized nations (Kokolis, 2006). Heart failure represents the end stage of 
cardiovascular disease and continues to have a high prevalence in the U.S. despite advances 
in medical therapy.  In developing countries, around 2% of adults suffer from heart failure, 
but in those over the age of 65, this increases to 6–10% (McMurray & Pfeffer 2005).  
Approximately 5 million Americans suffer from heart failure with over 550,000 new cases 
diagnosed each year (AHA, 2006).  Community-based surveys show that 30–40% of patients 
die within a year of diagnosis and 60–70% die within 5 years, most from worsening heart 
failure or suddenly (probably because of a ventricular arrhythmia) (McMurray & Pfeffer, 
2005). It is estimated that heart failure causes about 287, 0000 deaths in the US each year 
(AHA, 2006).  In addition to the loss of life, heart failure poses a significant financial burden 
with estimated annual direct costs in the U.S. of $35 billion dollars (AHA, 2006).  
Hospitalizations due to heart failure are increasing and this is expected to continue with the 
progressively aging population (Roger, 2004). 
Despite the advances in the management of heart failure, there may be as many as 100,000 
persons who have been treated with guidelines-based therapy but have remained relatively 
unresponsive in New York Heart Association (NYHA) Class IIIb or IV heart failure 
(O’Connell, 2009). Optimal therapy with angiotensin-converting enzymes inhibitors, 
angiotensin receptor blockers, beta blockers, aldosterone antagonists, nitric oxide enhancers, 
implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy have 
reduced hospitalizations and prolonged survival. However, the response is not uniform and 
at least a quarter of those who receive all therapies fail to respond (Hawkins, 2009).  In these 
end-stage heart failure patients with recurrent hospitalizations, few options exist.  
Aggressive surgical approaches including cardiac restraint devices, mitral valve repair, and 
surgical ventricular reconstruction are under evaluation but have yet to demonstrate 
definitive benefit (Mann et al., 2007);(Jones et al. 2009).  Only cardiac transplantation has 
been shown to definitively improve outcomes with median survival of 13 years, but this is 
restricted to a select relatively young population (Taylor et al., 2009).  The number of heart 
transplants in the U.S. has remained stable at about 2,000 per year, only 2% to 4% of patients 
who need definitive therapy.  With a growing population of end-stage heart failure patients 
and a static donor pool, it has become clear that heart transplantation will never meet the 
demands.  Although there is great enthusiasm for innovative approaches, stem cell therapy 
is only entering preliminary clinical trials, gene therapy of calcium transport proteins is only 
completing the first step in the cascade of clinical trials, and xenografting research has been 
stalled (O’Connell 2009). To date, the most promising area of development has been 
mechanical circulatory support with LVADs, most recently with the Thoratec HeartMate II. 
2.2 Left ventricular assist devices 
Implantable left ventricular assist devices have become accepted as an important 
therapeutic modality for patients with end-stage heart failure. The most common uses for 
LVADs include bridge to heart transplantation (BTT) and long-term destination therapy 
(DT) for those patients not eligible for transplantation.   
The development of ventricular assist devices began in earnest in 1964 with the National 
Institutes of Health establishment of the Artificial Heart Program, whose stated goal was 
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putting a man-made heart into a human being by the end of the decade (Sahuar 2004).  
Unlike the moon-landing, this lofty goal was not met. Nevertheless, progress proceeded 
slowly and clinical use of ventricular assist devices on a more routine basis began in the mid 
1980s.  Since then, the research and development of ventricular assist device technology, 
along with clinical progress, has accelerated.  Several LVADs have now been designed and 
developed and are in various phases of clinical and preclinical evaluation. Currently, 
implantable LVADs can be classified into two main categories: volume-displacement 
(pulsatile) and continuous-flow (nonpulsatile) pumps. All LVADs are composed of an 
inflow cannula, the actual pump with its associated mechanical and electrical components, 
an outflow conduit, a percutaneous lead, and the external system components with varying 
degrees of portability.  LVADs can also be grouped based on the engineering design of the 
pump with classification broadly as first-, second-, and third-generation devices (Nguyen & 
Thourani, 2010). First-generation devices are the pulsatile pumps. They include the 
HeartMate XVE and its predecessors including the HeartMate IP1000 and HeartMate VE 
(Thoratec Corp., Pleasanton, CA), the Thoratec PVAD and IVAD (Thoratec Corp.), and the 
Novacor LVAS (World Heart Corp., Oakland, CA). In contrast to the first-generation 
devices, both second- and third-generation LVADs are continuous flow, rotary pumps.  
Second-generation pumps, which include the HeartMate II (Thoratec Corp.), Jarvik 2000 
FlowMaker (Jarvik Heart, Inc., New York, NY), and MicroMed-DeBakey (MicroMed 
Cardiovascular, Inc., Houston, TX), have an internal rotor within the blood flow path that is 
suspended by contact, blood-immersed bearings. Third-generation devices are similar, but 
lack contact bearings in an effort to prevent wear and prolong device life without failure.  
Third-generation devices are in varying stages of clinical development, but are not available 
for commercial use in the U.S. 
First-generation LVADs came to clinical use in the mid 1980s and all of the first-generation 
devices listed above are approved for BTT. Despite this, only the HeartMate XVE is 
approved by the Food and Drug Administration for DT in the United States. As volume 
displacement pumps, first-generation LVADs have an internal reservoir chamber with 
inflow and outflow valves. The pumps function by cyclic filling and emptying of the 
reservoir chamber either by pneumatic or electrical drive systems.  More than 5000 pulsatile 
HeartMate devices have been implanted worldwide and have been shown to provide 
excellent hemodynamic support (Frazier et al., 2001). In several studies, mechanical 
circulatory support with these devices is reported to bridge patients successfully to 
transplant with a perioperative mortality of 15% to 20% and an overall survival until 
transplantation of 60% to 70% (El-Banayosy et al., 2000). Unfortunately, first-generation 
devices have inherent limitations in their design, particularly when used for the purpose of 
prolonged support or DT.  The pump size is quite large, thus requiring extensive surgical 
dissection with subsequent risk of hematoma formation and infection. The large size also 
limits implantation to patients with a large body habitus.  In addition, a large-diameter 
percutaneous lead is needed for venting of air, which can lead to an increased risk of 
driveline infections.  Finally, a critical drawback in first-generation devices is the high 
frequency of eventual device failure, requiring device exchange or causing possible death.  
In the landmark REMATCH trial, which was used as the basis for LVAD approval for DT, 
the failure rate of the HeartMate XVE after 2 years was 35%, with a mortality of more than 
10% attributed directly to device failure (Rose et al., 2001). 
The second-generation have now essentially replaced the first-generation devices for clinical 
use.  The most extensive clinical experience is with the HeartMate II.  Currently, this is the 
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only second-generation device approved for both BTT and DT in the United States (Miller et 
al., 2007); (Slaughter et al., 2009).  These continuous flow, rotary pumps were introduced to 
overcome many of the shortcomings of the first-generation devices.  They are simpler in 
design with only a single moving part: the internal rotor.  Advantages over first-generation 
devices include smaller size requiring less extensive surgical dissection for implantation, the 
absence of valves that are a primary site of wear, higher efficiency with less energy 
requirement, and a smaller percutaneous lead (Nguyen & Thourani, 2010).  With these 
improvements, the second-generation devices have shown to be much more reliable with 
device support of more than 6 years reported (Westaby et al., 2006).  While the necessity for 
device replacement does still occur with the HeartMate II, the underlying causes have been 
related to thrombosis, infection, or damage to the percutaneous leads and not to mechanical 
failures of the pumping mechanism (Slaughter et al., 2009).   In a recently-published 
randomized clinical trial for DT comparing the HeartMate II versus the first-generation 
HeartMate XVE, the HeartMate II was shown to be significantly better than the HeartMate 
XVE in achieving the primary end point of survival free from device failure or disabling 
stroke at 2 years (Slaughter et al., 2009).  Moreover, patients with HeartMate II support also 
had significantly superior actuarial survival rates at 2 years (58% vs. 24%). In addition, 
device failure and other complications including infections were less frequent in patients 
supported with the HeartMate II. 
3. Ventricular arrhythmias 
Mortality in patients with heart failure is mostly due to progressive heart failure or sudden 
death related to ventricular tachyarrhythmias (VAs) (Jessup, 2003).   The most important 
risk factor for VA is a reduced ejection fraction (EF) (Myerburg et al., 1997; Singh et al., 
2002).  Although medications such as beta-blockers, ACE inhibitors, and ARBs, and devices 
such as implantable cardiac defibrillators (ICDs) have been shown to decrease morbidity 
and mortality, the risk of sudden cardiac death (SCD) remains high.  In fact, approximately 
50% of patients with heart failure die from SCD (Guido et al., 1997).  
While the precise mechanism of ventricular tachyarrhythmias is not entirely understood, 
VAs are generally thought to originate from cardiac scar tissue and from the border between 
normal myocardium and scar tissue.  Ventricular scars are composed of variable regions of 
dense fibrosis that create conduction block and surviving myocyte bundles with interstitial 
fibrosis and diminished coupling, which produce the circuitous slow-conduction paths 
(Stevenson & Soejima, 2007).  The effective refractory period in the action potential of this 
borderline ischemic, viable myocardium is altered and bears the risk of generating the re-
entry circuits responsible for ventricular tachyarrhythmias (Doenst et al., 2007). 
In all patients with heart failure, the elevation of plasma catecholamines that cause increases 
in sympathetic outflow along with decrease in parasympathetic activity correlate well with 
poor prognosis.  Also significant in many patients are anatomic and mechanical factors such 
as wall stretch, abnormal wall motion, left ventricular stress, and increased myocardial 
length.  These factors acting directly, or through alterations in hemodynamic factors, may 
lead to the genesis of cardiac arrhythmias in the setting of heart failure (Damiano et al., 
1985).  All of these causative arrhythmogenic factors merge in the dilated and failing 
ventricle, creating a perfect storm for arrhythmogenesis. The immediate trigger for the 
development of VT or VF in an individual patient with heart failure is often unclear but a 
composite of the major interacting factors will reveal those patients at highest risk for 
sudden death. 
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To properly understand ventricular tachyarrhythmias, it is necessary to distinguish 
monomorphic ventricular tachycardia (MMVT) on one hand, and polymorphic ventricular 
tachycardia (PMVT) and ventricular fibrillation (VF) on the other.  Monomorphic VT is 
generally caused by fixed anatomic abnormalities such as scar from previous MI where 
border zone areas generate re-entrant circuits causing VT (Stevenson & Soejima, 2007).  This 
ventricular scar can be caused by ischemia or other forms of injury including scar tissue 
resultant from LVAD cannula placement.  In this case, 12-lead electrocardiogram and EP 
mapping can be used to localize specific areas of the ventricle where scar is present and re-
entrant VT is initiated.  On the other hand, PVT and VF are generally caused by a 
functionally deteriorating ventricle and result from repolarization abnormalities of the 
unhealthy myocardium (Aliot et al., 2009).  Congestive heart failure caused by the failing 
ventricle creates ventricular dilation, increase wall tension, and with that, conditions ripe for 
subendocardial ischemia.  These conditions alter the electric behaviour of the ventricle and 
can result in the disorganized contractions seen in PVT and VF.  As a result of the often 
direct anatomic correlation between MMVT and myocardial scar, MMVT is usually more 
receptive to targeted ablation therapies (Aliot et al., 2009).  Eliminating PMVT and VF is 
more difficult and often requires therapy guided toward functional improvement of the 
failing ventricle rather than ablation alone.   
4. Arrhythmias in patients with VADs 
4.1 Background 
The prevalence of ventricular arrhythmias is highest in those patients with severe end-stage 
heart failure: the same cohort of patients who stand to benefit most from LVAD therapy.  
Therefore, it should come as no surprise that ventricular arrhythmias are relatively common 
in patients supported with LVADs.  Despite this, the interaction between LVAD placement 
and ventricular arrhythmias is not well understood.  On one hand, LVAD placement does 
ease the burden on a diseased left ventricle by decompressing the ventricle.  This 
decompression in turn decreases the neurohormonal, hemodynamic, mechanical, and 
electrolyte abnormalities which predispose toward arrhythmia development; thereby 
reducing the frequency of post-op VTE, especially PMVT and VF.  In contrast, LVAD 
placement does not treat areas of existing ventricular scar, and indeed the apical cannula 
placement necessarily requires creation of new myocardial scar tissue.  This new scar tissue 
created by LVAD implantation places patients at risk for new monomorphic ventricular 
arrhythmias and does not impact existing MMVT resulting from other areas of scar.  Indeed, 
many reports suggest a higher incidence of ventricular arrhythmias in patients after LVAD 
placement (Ziv et al., 2005);(Andersen et al., 2009).  Postoperative ventricular 
tachyarrhythmia events (VTE) have been documented to occur in up to 35% of patients 
within 30 days of LVAD placement (Ziv et al., 2005);(Refaat et al., 2008).  
The pathogenesis of increased arrhythmias post-LVAD is likely to be caused by direct 
mechanical irritation from the inflow cannula of the LVAD as well as scar tissue from the 
cannula placement. With the LVAD in place the ventricle is decompressed and the aortic root 
pressure improved, resulting in improved blood flow to scarred regions of the heart and 
actually allowing for the tissue to conduct and support VT.  Post-VAD arrhythmias have also 
been attributed in the literature to a host of other mechanisms including acute left ventricular 
unloading with pulsatile VADs, altered ventricular repolarization (Grzywacz et al., 2006), 
mechano-electrical feedback from the VAD motor (Harding et al., 2001), and alterations in 
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calcium handling gene expression (Rodriguez-Way et al., 2005).  In addition, continuous flow 
devices are theorized to predispose to arrhythmias by causing so-called “suction events” when 
the ventricle is completely decompressed and the endocardium is sucked against the inflow 
cannula (Vollkron et al., 2007).  This suction phenomenon is thought to account for the 
apparent increased arrhythmia incidence with continuous flow LVADs as opposed to pulsatile 
LVADs.  While all of these theories are interesting and may contribute to the existing 
understanding of the interaction between LVADs and ventricular arrhythmias, the reality is 
that the current paucity of published literature and surplus of theories reflect an inadequate 
understanding of the relationship.  Most of the available data concerning arrhythmias in 
patients with LVADs constitute results from relatively small case series.  In addition, most of 
these case series review data from patients with pulsatile LVADs, while newer continuous 
flow devices such as the HeartMate II now dominate the national clinical practice.  
While the presence of an LVAD mitigates the profound hemodynamic collapse often seen in 
unsupported patients with VT or VF, studies have demonstrated a decrease in LVAD flow 
output with ventricular tachyarrhythmias (Bedi et al., 2007).  Additionally, crude mortality 
as high as 52% has been reported for patients with VT/VF within 1 week postoperatively 
(Bedi et al., 2007).  Ventricular tachyarrhythmias can reduce right ventricle output, thereby 
reducing left ventricular venous return.  Therefore, even though the left ventricle is 
supported by the LVAD, the arrhythmia prevents adequate preload on left ventricle and can 
become hemodynamically unstable.  Thus, elimination of ventricular tachyarrhythmias in 
LVAD patients is essential to maximizing outcomes.  
4.2 Literature review 
In order to begin understanding the relationship between ventricular arrhythmias and 
LVADs it is necessary to review of the existing literature.  In 1991, the first known report of 
ventricular arrhythmias in patients with LVADs was published (Arai et al., 1991).  In 1994, 
Oz et al. reported that ventricular arrhythmias are well tolerated in the immediate setting in 
patients LVAD support. Pulmonary perfusion was maintained even during rapid 
ventricular arrhythmias and cardiac arrest was well tolerated without syncope.  Thus, 
delayed termination of ventricular fibrillation or flutter was reported to be safe and feasible 
in this setting (Oz et al., 1994).  In 1997, the first case report documenting benefit from an 
implantable cardioverter-defibrillator (ICD) in a patient on LVAD support was published in 
a 51 year-old male who underwent LVAD implantation for refractory heart failure after 
having received an ICD five years earlier (Skinner et al., 1997).   
Following these reports, it took until 2005 for a relatively large retrospective observational 
study to be performed (Ziv et al., 2005).  This study remains of the best available, and 
reported a 32% incidence of VT/VF following pulsatile LVAD implantation for advanced 
heart failure, with particularly high rates during the early post-operative period (Ziv et al., 
2005).  Notable in this study was the comparison of pre-operative arrhythmias to post-
operative arrhythmias.  One hundred and eighteen episodes of documented sustained 
ventricular arrhythmia occurred in 30 (of 100) patients pre-operatively, one hundred and 
seventy nine episodes occurred in 32 patients post-operatively.  Of those 9 patients with pre-
operative MVT, 4 patients no longer had MVT and 5 continued to have MVT after LVAD.  
New-onset MVT was documented in 18 patients who had no pre-LVAD MVT, 12 of whom 
had no pre-LVAD arrhythmia of any type.  With regards to PVT and VF, 23 patients had 
PVT/VF documented pre-operatively and 17 patients had PVT/VF post-operatively.  
PVT/VF was no longer observed in 16 patients who had this arrhythmia before LVAD 
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placement, whereas PVT/VF was a new finding in 10 patients who had not had this 
arrhythmia documented pre-operatively.   
Summarizing these results, in 100 patients undergoing pulsatile LVAD implantation, there 
was a slight decrease in post-operative PVT/VF and a significant increase in post-operative 
MVT.  This is exactly as one might expect given the LVADs role in decompression of the 
ventricle helping with PVT/VF, but creating a new site of scar and mechanical irritation in the 
ventricle and causing a new focus for MVT.  In addition, the majority of the 32 patients who 
had post-LVAD ventricular arrhythmias had experienced the first episode by the end of the 
first postoperative week.  Post-LVAD ventricular tachyarrhythmia was nearly incessant in 9 
patients and highly frequent (>5 episodes/day) in 7 patients.  Whereas the total number of 
patients with ventricular tachyarrhythmias of any kind before and after LVAD was similar, 
post-LVAD arrhythmias were more frequent and resistant to drug treatments.  Trends were 
observed in all-cause mortality and stroke, but no statistically significant relationship between 
arrhythmia and these outcomes was demonstrated (Ziv et al., 2005). 
The above retrospective review was followed by another retrospective review of 111 
consecutive patients undergoing pulsatile LVAD placement for BTT between 1987 and 2001 
(Bedi et al., 2007).  In this study, clinically significant ventricular arrhythmias occurred in 24 
patients (22%) during device support.  54% of these occurred during the first week post-
implantation.  The mortality was significantly higher (p<0.001) during LVAD support in the 
group with ventricular arrhythmias (33%) vs. the group without ventricular arrhythmias (18%).   
In 2008 a smaller retrospective review of 42 patients (Refaat et al., 2008) documented post-
operative ventricular arrhythmias in 15 patients (36%).  Analysis of multiple pre- and post-
operative factors revealed that non-usage of post-operative beta-blockade was strongly 
associated with arrhythmia development (odds ratio 7.04, p=0.001).  Unfortunately, this 
association has not been borne out in subsequent studies. 
A 2009 retrospective review represents the first published description of ventricular 
arrhythmias in continuous flow LVADs.  This study reviewed records of 23 consecutive 
HeartMate II recipients and documented a 52% incidence (12 of 23) of sustained VT or VF 
(Anderson et al. 2009).  75% of the patients experienced the arrhythmia within 4 weeks, and 
in all of these patients the arrhythmia predicted recurrent arrhythmic events.  None of these 
patients died of the arrhythmia but most were symptomatic during the event.  32% of the 
patients required cardioversion or defibrillation.  Based on the high incidence of post-
operative arrhythmias, along with the fact that 3 patients experienced hemodynamic 
instability associated with the event, the authors recommended consideration for 
prophylactic ICD implantation for all patients expected to be supported by the LVAD for a 
longer period of time (Anderson et al 2009).  
Other more recent reviews have concurred with Anderson et al.’s assertion that ICD 
implantation should be considered for primary prevention of VT/VF in all patients 
undergoing LVAD implantation. A Cleveland clinic review looked at all 478 patients 
undergoing VAD placement between 2001 and 2008; the majority (74%) of these being 
pulsatile LVADs, 8.2% continuous-flow, and 10.5% with extracorporeal systems (Cantillon 
et al, 2010).  90 of these patients (18%) had an ICD at the time of VAD implantation.  Crude 
mortality was lower among patients with an ICD (24.4%) when compared to those without 
an ICD (36.9%; P=0.026), Kaplan-Meier curve for survival shows divergence between 
patients with and without ICD beginning at 20 days and extending throughout the support 
period.  32% of the patients experienced a sustained ventricular tachyarrhythmia event in 
the post-operative period with the mean time to first event being 32.4 +/- 47.1 days.  While 
www.intechopen.com
 Ventricular Assist Devices 
 
144 
the retrospective nature and large cohort of patients with pulsatile LVADs limit the review, 
the survival difference in a large number of patients is intriguing.  
The only prospective study looking at ventricular arrhythmias in LVAD patients is a 
recently published study from Hanover Germany. 61 consecutive patients underwent 
LVAD implantation between 2005 and 2008, 44 of these patients with the HeartMate II and 
15 with the Heartware LVAD, a third-generation continuous-flow device (Oswald et al., 
2010).  After the acute perioperative period, all patients without a pre-existing ICD (40 
patients) underwent ICD implantation (17 +/- 15 days after VAD placement). Ventricular 
arrhythmias leading to ICD interventions were frequent in the study population with 34% of 
patients receiving appropriate ICD interventions for ventricular arrhythmias during the 
study follow-up (median 12 months; range 13-1167 days).  Even excluding the first 7 days 
when patients were most prone to arrhythmias, there was a still a 25% rate of appropriate 
ICD interventions.  Observed arrhythmias were 52% monomorphic VT, 35% VF, and 13% 
polymorphic VT.  Of the 21 patients with appropriate ICD interventions, there were a total 
of 144 episodes of spontaneous ventricular arrhythmias (average 6.8 per patient).  Patients 
with no previous arrhythmia history had an estimated 1-year risk of 24% for appropriate 
ICD treatment, those with a secondary prevention indication had an even higher 1-year risk 
of 50%.  In these secondary prevention patients, the calculated VTE rate per month was the 
same both before and after VAD placement.  Interestingly, ventricular arrhythmia rate was 
higher in nonischemic heart failure (50%) than ischemic heart failure (22%) patients. 
The observations from all of the above studies yield more questions than answers; however, 
several basic conclusions can be drawn from them.  First, sustained ventricular arrhythmias 
are common in patients after LVAD implantation with a range of 22% to 52% of patients 
experiencing sustained VT/VF in the post-operative period.  Second, most patients who 
experience post-operative VT/VF do so within the first few weeks after surgery.  Third, 
patients who experience one episode of sustained VTE are more likely to experience future 
events. Fourth, while ventricular arrhythmias seem to better tolerated in the LVAD 
population as compared to patients without assist devices, most ventricular arrhythmias do 
have associated symptoms, some cause hemodynamic instability, and all may impact long 
term survival and survival to transplantation. Fifth, prophylactic ICD placement may be 
indicated and a prospective randomized trial is needed to answer this question. Finally, as is 
always the case with any emerging medical technology, further prospective analysis is 
needed.           
5. Arrhythmia treatment 
5.1 Arrhythmia surgery 
Cardiac surgery for arrhythmias was initiated in 1968 by Dr. Will Sealy with the first 
successful division of an accessory AV connection for the Wolff-Parkinson-White (WPW) 
syndrome.  During the 1980s hundreds of cardiac surgeons learned the technique of open-
chest surgical division of accessory AV pathways for the cure of WPW syndrome.  However, 
as the 1980s ended, catheter-based radiofrequency ablation (RFA) emerged as a less invasive 
method of cure and Dr. Sealy’s surgery was relegated to a historical footnote (Cox J, 2004).  
Subsequently, Cox and colleagues attained the first clinical cure of an AV nodal reentrant 
tachycardia in 1982 via a discrete cryosurgical procedure (Cox et al., 1987).  Again, catheter-
based RFA rapidly replaced the use of cryosurgery specifically for the treatment of AV 
nodal reentrant tachycardias.  Nevertheless, this initially use of cryothermal energy in 
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cardiac surgery opened the door for other uses of cryosurgery throughout the 1980s and 
1990s for treatment of other supraventricular tachyarrhythmias, atrial tachyarrhythmias via 
the Cox-Maze procedure, and ventricular arrhythmias via destruction of ectopic foci of 
excitation (Cox J, 2004).   
Experiments in the 1960s had documented the heterogeneity of tissue injury in acute MI and 
the reentrant basis of ischemic ventricular arrhythmias was defined (Han et al., 1970);( 
Boineau & Cox, 1973).  During the 1970s, it became apparent that simple revascularization 
with CABG failed to cure ischemic ventricular tachyarrhythmias and that revascularization 
alone had prohibitively high morbidity and mortality.  In 1969, Kaiser and colleagues 
reported on intraoperative mapping in patients with heart disease to localize the area of 
ischemia injury (Kaiser et al., 1969).  A decade later, Harken and associates described the 
endocardial resection procedure based on intraoperative mapping (Josephson et al., 1979).  
In the late 1980s, Dor and colleagues described the technique of both surgical resection and 
repair of LV aneurysms (Dor et al., 1989).  Part of Dor’s described procedure included 
cryoablation of the junction of scar and normal myocardium if spontaneous or inducible 
tachycardia was present preoperatively.  When reporting on results of this procedure, the 
unexpected effect was that arrhythmias were essentially cured without need for 
intraoperative mapping (Dor et al., 1994).   While ischemic VT remains the most common 
surgically treated ventricular arrhythmia to this day, these surgical procedures are only 
rarely performed primarily to treat arrhythmia.  Most often, there is another primary 
indication, such as the improvement of left ventricular function (via the Dor procedure), the 
removal of apical thrombus, or the alleviation of heart failure symptoms (Doenst et al., 
2007).  Subsequent advances in the field of electrophysiology have replaced many open 
surgical techniques for the treatment of arrhythmias, however the use of open cryosurgery 
for treatment of ventricular arrhythmias in the Dor procedure, and for treatment of atrial 
fibrillation via the Cox-Maze procedure has persisted (Cox J, 2004).   
5.2 Mechanism of cryoablation 
Cryothermal energy is the preferred energy source for arrhythmia ablation in open cardiac 
surgery. Cryothermal energy destroys tissue through the formation of intracellular and 
extracellular ice crystals. These crystals disrupt the cell membrane and the cytoplasmic 
organelles. Following cryoablation, there is development of hemorrhage, edema, and 
inflammation over the first 48 hours.  Healing is characterized by extensive fibrosis, which 
begins approximately 1 week after lesion formation. Cryoablation is the only available 
energy source that does not disrupt tissue collagen, thus preserving normal tissue 
architecture (Lall & Damiano, 2007).  This makes it an excellent energy source for ablation 
close to valvular tissue or the fibrous skeleton of the heart.  Histologically, cryoablation 
creates a dense homogenous scar which has been shown to have a low arrhythmogenic 
potential (Wetstein et al., 1985).   
With conventional nitrous oxide cryoablation probes, 2 to 3 minute ablations have been 
shown to reliably create transmural atrial lesions and penetrate ventricular muscle to 
adequate depths for effective and reliable ablation.  Nitrous oxide cryoablation has a history 
of extensive clinical use and an excellent safety profile.  Thus the benefits of cryoablation 
include the ability to preserve tissue architecture and collagen structure, as well as a well-
defined dose curve and safety profile.  The potential disadvantage is the relatively long time 
necessary to create an ablation (2 to 3 minutes). 
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Two commercially available sources of cryothermal energy are available for use in cardiac 
surgery. The older, and more proven, technology utilizes nitrous oxide and is manufactured 
by Cooper Surgical, now recently purchased by AtriCure® (Cincinnati, OH).  A variety of 
rigid and malleable probes are available for use.  More recently, CryoCath Technologies 
(Montreal, Canada) developed a device using argon gas. This technology uses either a 
malleable probe or a two-in-one convertible device that incorporates a clamp and surgical 
probe. At one atmosphere of pressure, nitrous oxide is capable of cooling to -89.5°C, 
whereas argon has a minimum temperature of -185.7°C.  Both types of probes consist of a 
hollow shaft, an electrode tip, and an integrated thermocouple for distal temperature 
recording. The liquid is pumped under high pressure to the electrode through an inner 
lumen. Once the fluid reaches the electrode, it converts to a gas phase, absorbing energy and 
resulting in rapid cooling of the tissue.  The gas is then aspirated by vacuum through a 
separate return lumen to the console (Lall & Damiano, 2007).  In our protocol, the AtriCure 
device was used with the malleable Cryo1™ probe.  The probe is applied to the relevant 
areas selected for ablation and either a 2 or 2.5 minute cycle is used.  
6. Our treatment protocol 
6.1 The problem 
Over the last 21 months, we have implanted 51 continuous flow HeartMate II LVADs at the 
University of Virginia. Following the first dozen HeartMate II implantations, we anecdotally 
noted that the rate of post-operative ventricular arrhythmias seemed higher than with the 
previously used HeartMate XVE, a pulsatile LVAD. Therefore, after the first 23 
implantations of the HeartMate II, we analyzed our single-institution data and noted that 
the rate of post-operative VT and VF was higher in the HeartMate II population as 
compared to the 14 previously placed HeartMate XVE LVADs. 34.7% (n=8) of the 
HeartMate II patients had recurrent post-operative VT/VF, while 21.4% (n=3) of the 
HeartMate XVE patients had recurrent post-operative VT/VF.  Importantly, pre-operative 
rates of VT/VF were the same in both groups (35%). While this difference did not 
demonstrate statistical significance, we decided that in conjunction with published data 
confirming a high rate of VT/VF in post-operative patients with continuous flow LVAD and 
the potential association of these events with poor outcomes, we needed to become more 
aggressive in treating for ventricular arrhythmias at the time of LVAD placement. Our 
group sought to devise with a method to reliably decrease, or completely prevent, the 
incidence of post-operative ventricular tachyarrhythmias. Through a combination of 
catheter-based EP approaches along with open surgical ablation techniques, we began 
instituting a protocol for open cryoablation of mapped arrhythmia loci at the time of LVAD 
implantation.   
6.2 Catheter mapping and ablation 
There are several methods for ablating a focus of ventricular tachycardia as mentioned 
previously.  The most common method of ventricular arrhythmia treatment in all patients is 
via EP catheter-directed mapping and RFA of identified areas of endocardial border zone 
ischemic tissue (scar mapping) or RFA of other identified foci of arrhythmogenic substrate 
(activation mapping). While this represents the least invasive of potential methods for 
ablation of VT/VF, it suffers from several shortcomings, especially in the LVAD population.  
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First, with a continuous flow LVAD in place, such as the HeartMate II, the left ventricle is 
decompressed.  In this decompressed left ventricle with the LVAD inflow cannula in the 
apex of the ventricle, there is very little room to maneuver the ablation catheter (see Figure 
1), thus making the procedure exceedingly difficult despite the fact that reducing the LVAD 
flow can mitigate this issue.  Second, traditional catheter-based RFA offers access only to 
endocardial sources of arrthymogenic tissue.  Evidence shows that up to 70% of patients 
with ventricular tachycardia have epicardial substrate as the source of their arrhythmia, 
especially those patients with non-ischemic cardiomyopathies (Sacher et al., 2009).  While 
trans-cutaneous catheter-based epicardial ablation of ventricular tachycardia via a sub-
xiphoid approach is becoming a more frequently used technique at our institution and 
others, it is associated with several complications including post-procedure atrial fibrillation 
and pericarditis, right ventricle puncture during access, and others (Aliot et al., 2009; 
Mahapatra et al., 2009).  Third, it is difficult to reliably create transmural ventricular lesions 
using a catheter-based RFA approach.  Therefore, post-operative catheter-based RFA for 
LVAD-associated ventricular arrhythmias suffers from too many shortcomings to be the 
primary method of ventricular tachyarrhythmia treatment in LVAD patients. 
 
 
Fig. 1. Echocardiography demonstrating EP catheter in decompressed ventricle 
6.3 Other options 
Alternatively, given the difficulties and shortcomings associated with catheter-directed 
RFA, intra-operative ablation of arrhythmogenic substrate can be performed.  Ideally this 
would be performed using simultaneous intra-operative EP scar mapping to identify areas 
of substrate to maximize the efficacy of cryoablation; however, this technique would require 
a hybrid EP suite and surgical operating room which is not available at our institution.  A 
second option is mapping prior to planned LVAD implantation to define targeted areas for 
intra-operative cryoablation. Following localization of arrhythmogenic substrate via EP 
mapping or EKG analysis, patients can then undergo intra-operative cryoablation of the 
arrhythmia focus at the time of LVAD implantation.   
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As mentioned previously, arrythmia surgery has in large part been replaced by catheter-
directed EP therapies.  However, in a case where another primary indication exists that 
requires sternotomy or thoracotomy with open access to the heart with or without 
cardiopulmonary bypass, arrhythmia surgery has remained as a mainstay of treatment.  
Examples of this include cryoablation at the time of surgical ventricular reconstruction, as seen 
in the Dor procedure, and the Cox-Maze procedure for atrial fibrillation performed in 
conjunction with mitral valve repair or replacement.  We argue that LVAD implantation offers 
and equally opportune occasion for arrhythmia treatment via an open surgical approach.  
6.4 Substrate mapping technique 
Prior to any planned arrhythmia intervention, one must identify the target area for 
treatment. In our experience, this is done with either targeted EP mapping and/or 
systematic EKG interpretation. Using an established technique of electrophysiologic 
substrate mapping, a detailed schematic map of the heart is generated (Figures 3 and 4).  
This map is generated by measuring endocardial voltage potentials at a variety of locations.  
In the generated map, voltages greater than 1.5mV represent normal cardiac tissue and 
appear purple; voltages less than 0.5mV represent dead cardiac muscle and appear red; and 
voltages in between represent the borderline ischemic areas and are represented by a range 
of colors (Aliot et al., 2009).  After substrate mapping is completed, the electrophysiologist 
and surgeon are able to carefully review the generated projection and can specifically target 
the border zone areas of potentially arrhythmogenic substrate for open intra-operative 
cryoablation at the time of LVAD placement.  Note in figure 2 the visualized EP mapping 
catheter.  In a hybrid EP suite/Operating room, the surgeon would be able to visualize and 
palpate the intra-cardiac catheter at the time of mapping in order to very specifically target 
the mapped arrhythmogenic substrate in real time. 
Unfortunately, a hybrid suite is not available at this time and not all patients are stable 
enough to tolerate transport to, and mapping in, the EP suite. Given this logistic issue, we 




Fig. 2. Electrophysiologic Substrate Map 
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substrate. In patients with hemodynamic instability who would not tolerate substrate 
mapping in the EP suite, a systematic interpretation of 12-lead EKG results capturing 
episodes of ventricular arrhythmia is performed.  Systematic EKG analysis of captured 
ventricular arrhythmia events is then used to localize the arrhythmia origin to an anatomic 
area of the heart (i.e. LV lateral wall).    
Using Figure 3 as a guide, and Figure 4 as an example of sustained monomorphic VT, one 
first looks at lead V1.  If a left bundle branch block (LBBB) is visible, the arrhythmia source 
comes from the RV or septum; if a right bundle branch block (RBBB) is visible, the 
arrhythmia is generated in the LV.  One can then look at the direction of deflection of the 
QRS complex to more specifically localize the arrhythmia focus.  First, looking at the inferior 
leads, II, III, and avF, a positive wave localizes the focus to the anterior aspect of the LV.  
Alternatively, a negative wave indicates posterior LV. Similarly, the precordial leads are 
analyzed and a positive deflection in avR and V4 indicates an apex source, a negative 
deflection points to the base of the ventricle. Finally, lead I and avL are analyzed, with a 
positive deflection indicating a septal source, a negative deflection pointing to a lateral wall 
source. In this manner, the focus of arrhythmogenic substrate can be localized to a specific 
area of the heart that allows the surgeon to target this area intra-operatively with 
cryoablation. For example, using Figure 4 below, the 12-lead EKG of captured ventricular 
tachycardia can be used to localize the arrhythmia source to the apical LV antero-lateral 
wall.  RBBB points to the LV, then inferior leads point to the anterior surface, then precordial 
leads indicate an apical source, then I and avL point to the septum. Therefore, the LV 
antero-lateral wall close to the apex is the likely source. 
   
 
 
Fig. 3. Schematic for 12-lead EKG analysis of captured VT. 
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Fig. 4. Monomorphic Ventricular Tachycardia localizing to LV antero-lateral wall. 
6.4 Intra-operative cryoablation 
LVAD implantation surgery offers a unique opportunity for arrhythmia treatment because 
of the open access the surgeon is granted to the entire epicardial surface of the heart and the 
endocardium of the entire left ventricle.  In addition, one can proceed with cryoablation 
with relative impunity on the left ventricle because the LVAD will be in place post-
operatively.  Given the role of the LVAD in supporting the already failed left ventricle, the 
preservation and optimization of post-operative left ventricular function does not carry the 
same supreme importance associated with virtually every other cardiac surgery performed.   
A common cause of morbidity and mortality in patients with LVADs is RV failure, so care 
must be exercised to avoid unnecessary ablation on the septum and free wall of the RV, but 
otherwise one may proceed without excessive concern of damaging healthy myocardium. 
The procedure is performed in the same manner as any other LVAD implantation. A 
median sternotomy is performed followed by pericardiotomy and the preperitoneal pocket 
is made to accommodate the LVAD pump.  Following this, cannulation sutures for 
cardiopulmonary bypass are inserted, anticoagulation is dosed, cardiopulmonary bypass 
cannulae are placed, and partial bypass is initiated.  Once partial bypass is initiated, 
epicardial cryoablation is performed using the AtriCure device with the Cryo1 probe.  Each 
pre-identified site of arrhythmogenic substrate is ablated at -70°C for two and a half 
minutes.  If necessary, the malleable Cryo1 probe can be shaped to match the contour of the 
epicardial surface to facilitate uniform application of the cryothermal energy (see Figure 5).  
Following epicardial ablation, full bypass is initiated, the aorta is cross-clamped, and 
cardioplegia is administered.  We prefer to perform the endocardial ablation and LVAD 
placement on the arrested heart, although these procedures can also be done on the empty 
beating heart.  At this point, the left ventricle apex is identified and the coring device is used 
to create a ventriculotomy for placement of the LVAD inflow cannula. Subsequently, the 
AtriCure device is again used with the Cryo1 probe for endocardial ablation via the 
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Fig. 5. Epicardial Cryoablation 
previously-performed ventriculotomy (see Figure 6).  For endocardial ablation in the 
arrested and non-perfused heart, we opt to reduce cryo time to two minutes, again at -70°C.  
For effective arrhythmia ablation, care must be taken to ablate the previously identified 
arrhythmogenic site in addition to creating a surrounding cryoablation tract extending to 
fixed anatomic sites such as the mitral valve and/or apical LVAD inflow cannula site.  
Ablation at an arrhythmogenic scar site only, without this extension, could leave the patient 
prone to recurrent arrhythmias via reentrant conduction around the ablated scar site.  
Following completion of the endocardial ablation, circumferential stitches are placed at the 
ventriculotomy, the LVAD inflow cannula is seated, and the remainder of the surgery for 
standard LVAD placement proceeds as per usual. 
7. Results 
Since instituting the above protocol for the prevention of post-operative ventricular 
arrhythmias, we have performed 28 additional HeartMate II LVAD implantations.  Of these 
28 patients, 9 patients had a history of previous VT/VF and thus underwent pre-operative 
mapping and intra-operative endocardial and epicardial cryoablation. None of these 9 
patients who underwent intra-operative cryoablation have suffered from sustained post-
operative ventricular arrhythmias.  Of the 21 patients who had no history of pre-operative 
VT/VF, 3 patients experienced post-operative sustained VT or VF.  In all 3 of these cases, the  
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Fig. 6. Endocardial Ablation 
 
Fig. 7. Treatment Protocol 
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patients were asymptomatic, the arrhythmias were easily controlled with medical therapy, 
were not recurrent, and did not require additional intervention. None of the 28 patients 
required additional catheter-based interventions for arrhythmia control.  Prior to instituting 
this protocol for intra-operative cryoablation, 8 of 23 patients (34.7%) required intervention 
for recurrent post-operative ventricular tachyarrhythmias.  After initiating the protocol 0 of 
28 patients required further intervention.  It is still too early to know whether and how this 
procedure has impacted other results; however, it is clear that directed intra-operative 
cryoablation is useful in decreasing the rates of post-operative ventricular tachyarrhythmias 
following HeartMate II LVAD implantation. 
8. Future direction 
The protocol, technique, and results presented above show promise toward the goal of 
eliminating ventricular tachyarrhythmias following LVAD placement. Admittedly, our 
experience with this technique is in its infant status and we will develop further refinements 
as we implant more devices and gain clinical experience managing patients with LVADs 
and with ventricular tachyarrhythmias. The first question we will have to address is 
whether to ablate all patients at the time of LVAD implantation, not just those with a prior 
history of ventricular tachyarrhythmias. Previous studies had demonstrated that the 
patients who experience problems with post-operative ventricular arrhythmias are not 
necessarily the same patients with a history of ventricular tachyarrhythmias pre-operatively 
(Ziv et al., 2005);(Oswald et al., 2010).  In the only prospective study to date, Oswald et al. 
demonstrated that patients with no previous arrhythmia history had an estimated 1-year 
risk of 24% for appropriate ICD treatment for sustained VT or VF following continuous flow 
LVAD placement.  Other studies have shown similar rates of new ventricular arrhythmias 
following LVAD placement.   
In our experience, although limited, we have not seen any patients with clinically significant 
VT or VF requiring additional catheter-based therapy in either group.  Only time will tell 
whether this is a sustained finding with our methodology.  Notably in the Dor experience, 
the incidence of post-operative ventricular arrhythmias is less than 2% (Dor et al., 1994).  
Similar to our approach to cryoablation, in the Dor procedure for ventricular reconstruction 
for ischemic heart failure, only those patients who have a history of previous sustained VT 
or VF undergo cryoablation of the border zone surrounding the resected myocardium.  In 
1994, Dor and colleagues reported on 287 who patients underwent programmed ventricular 
stimulation prior to subtotal endocardiectomy with surgical ventricular reconstruction.  106 
patients were found to have inducible (57) or spontaneous (49) ventricular tachycardia pre-
operatively; however, ventricular tachycardia was no longer inducible in 92% of patients 
after operation and only two patients had spontaneous ventricular tachycardia after the 
operation (Dor et al., 1994).  Subsequent studies have replicated this result (Sartipy et al., 
2005).  It is unclear exactly why the Dor procedure is so successful in limiting the prevalence 
of post-operative arrhythmias.  Logic suggest that the reconstructed ventricle experiences 
less wall stress and with that, the neurohormonal, mechanical, and hemodynamic 
conditions which predispose to arrhythmia generation are eliminated.  In addition, 
cryoablation destroys the border-zone ischemic tissue where monomorphic VT may be 
generated.  If this is the case for the Dor procedure, our approach to HeartMate II LVAD 
implantation with cryoablation may replicate the same results.   
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Regardless of whether these results bear out over the long term, this chapter should 
demonstrate that the management and treatment of ventricular arrhythmias in the LVAD 
population will be an important topic for the heart failure specialist, electrophysiologist, 
and cardiac surgeon to understand over the coming decades.  Destination therapy is here 
to stay.  With over half a million Americans suffering from heart failure, and over 100,000 
in NYHA class IIIb or IV heart failure, the pool of patients who may benefit from 
ventricular assists devices is large.  In addition, with over 550,000 people newly 
diagnosed with heart failure each year and an aging population, all of these numbers 
stand to expand over the coming years.  The benefit of LVAD implantation is clear with 
large trials now showing two-year HeartMate II survival rates of almost 60% in a 
population which only ten years ago had a survival rate of 8% with optimal medical 
therapy (Slaughter et al., 2009);(Rose et al., 2001).  With third-generation non-contact 
bearing devices now approved in Europe and on the horizon in the U.S., LVAD survival 
and quality of life may soon eclipse the gold standard for heart failure treatment: heart 
transplant.  In order for this to happen, issues such as post-operative ventricular 
arrhythmias need to be worked out.  We believe that following our approach will 
significantly limit the prevalence of post-operative ventricular tachyarrhythmias, but the 
nuances of patient selection and procedure performance have room for development.  
Only with multi-institutional prospective trials will the true answers be known: who to 
treat, how to map, and where and how to ablate.  We hope definitive answers will be 
known soon and that ventricular arrhythmias in patients with ventricular assist devices 
will become only a historical footnote.  Until then, we push on.      
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